Results 141 to 150 of about 349,757 (388)

Prospective effect of linkers type on the anticancer activity of pemetrexed-monoclonal antibody (atezolizumab) conjugates [version 2; peer review: 2 approved, 1 approved with reservations]

F1000Research
Background Conventional chemotherapy results in severe toxic side effects due to affecting normal and cancer cells. The conjugation of chemotherapy with mAb will improve the chemotherapy selectivity towards cancer cells and at the same time will ...
Nidhal K. Maraie, Basma Talib Al-Sudani, Faten Q. Ibraheem, Ayad M.R. Raauf   +3 more
doaj   +1 more source

Chemically triggered drug release from an antibody-drug conjugate leads to potent antitumour activity in mice

Nature Communications, 2018
Current antibody-drug conjugates (ADCs) target internalising receptors on cancer cells leading to intracellular drug release. Typically, only a subset of patients with solid tumours has sufficient expression of such a receptor, while there are suitable ...
R. Rossin, Ron M. Versteegen, Jer-Cheng Wu, Alisher Khasanov, Hans J. Wessels, E. J. Steenbergen, W. ten Hoeve, H. Janssen, Arthur H. A. M. van Onzen, P. Hudson, M. Robillard   +10 more
semanticscholar   +1 more source

Transcriptional network analysis of PTEN‐protein‐deficient prostate tumors reveals robust stromal reprogramming and signs of senescent paracrine communication

Molecular Oncology, EarlyView.
Combining PTEN protein assessment and transcriptomic profiling of prostate tumors, we uncovered a network enriched in senescence and extracellular matrix (ECM) programs associated with PTEN loss and conserved in a mouse model. We show that PTEN‐deficient cells trigger paracrine remodeling of the surrounding stroma and this information could help ...
Ivana Rondon‐Lorefice, Jose I. Lopez, Aitziber Ugalde‐Olano, Maite Zufiaurre, Ianire Astobiza, Natalia Martin‐Martin, Laura Bozal‐Basterra, Saioa Garcia‐Longarte, Amaia Zabala‐Letona, Sofia Rey, Aida Santos‐Martin, Miguel Unda, Ana Loizaga‐Iriarte, Mariona Graupera, Paolo Nuciforo, Arkaitz Carracedo, Isabel Mendizabal   +16 more
wiley   +1 more source

Bystander killing effect of DS‐8201a, a novel anti‐human epidermal growth factor receptor 2 antibody–drug conjugate, in tumors with human epidermal growth factor receptor 2 heterogeneity

Cancer Science, 2016
Antibody–drug conjugates deliver anticancer agents selectively and efficiently to tumor tissue and have significant antitumor efficacy with a wide therapeutic window.
Y. Ogitani, K. Hagihara, Masataka Oitate, H. Naito, T. Agatsuma   +4 more
semanticscholar   +1 more source

Exploiting metabolic adaptations to overcome dabrafenib treatment resistance in melanoma cells

Molecular Oncology, EarlyView.
We show that dabrafenib‐resistant melanoma cells undergo mitochondrial remodeling, leading to elevated respiration and ROS production balanced by stronger antioxidant defenses. This altered redox state promotes survival despite mitochondrial damage but renders resistant cells highly vulnerable to ROS‐inducing compounds such as PEITC, highlighting redox
Silvia Eller, Susanne Ebner, Carmen Haselrieder, Julia K. Günther, Astrid Drasche, Sophie Strich, Chiara Volani, Andrea Medici, Aleksandar Nikolajevic, Alex Deltedesco, Johannes E. Sigmund, Michael J. Blumer, Martin Hermann, Johanna Vanacker, Gerald Brandacher, Eduard Stefan, Omar Torres‐Quesada, Jakob Troppmair   +17 more
wiley   +1 more source

Phase I study of the anti-FcRH5 antibody-drug conjugate DFRF4539A in relapsed or refractory multiple myeloma

Blood Cancer Journal, 2019
FcRH5 is a cell surface marker enriched on malignant plasma cells when compared to other hematologic malignancies and normal tissues. DFRF4539A is an anti-FcRH5 antibody-drug conjugated to monomethyl auristatin E (MMAE), a potent anti-mitotic agent. This
A. Stewart, A. Krishnan, S. Singhal, R. Boccia, M. Patel, R. Niesvizky, A. Chanan-Khan, S. Ailawadhi, J. Brumm, K. Mundt, K. Hong, J. McBride, Quyen Shon-Nguyen, Yuanyuan Xiao, V. Ramakrishnan, A. Polson, D. Samineni, D. Leipold, E. Humke, J. Mcclellan, J. Berdeja   +20 more
semanticscholar   +1 more source

Cell surface interactome analysis identifies TSPAN4 as a negative regulator of PD‐L1 in melanoma

Molecular Oncology, EarlyView.
Using cell surface proximity biotinylation, we identified tetraspanin TSPAN4 within the PD‐L1 interactome of melanoma cells. TSPAN4 negatively regulates PD‐L1 expression and lateral mobility by limiting its interaction with CMTM6 and promoting PD‐L1 degradation.
Guus A. Franken, Andrea Abel Gutierrez, Imke van Rossum, Cornelia G. Spruijt, Michiel Vermeulen, Guido van Mierlo, Blanca Scheijen, Annemiek B. van Spriel   +7 more
wiley   +1 more source

Nodular Regenerative Hyperplasia Induced by Trastuzumab Emtansine: Role of Emtansine?

Annals of Hepatology, 2018
Trastuzumab is a monoclonal antibody targeted against the Human Epidermal Growth Factor Receptor 2 (HER2) overexpressed in some breast cancer. This targeted therapy significantly improves the prognosis of these cancers. Recently an anti-HER2 antibodydrug
Marion Lepelley, Marion Allouchery, Jérôme Long, Dorothée Boucherle, Yves Ranchoup, François Le Marc’Hadour, Céline Villier, Nathalie Sturm   +7 more
doaj   +1 more source

Supplementary Data from Antibody–Drug Conjugate Sacituzumab Govitecan Drives Efficient Tissue Penetration and Rapid Intracellular Drug Release

, 2023
Anna Kopp, Scott Hofsess, Thomas M. Cardillo, Serengulam V. Govindan, Jennifer Donnell, Greg M. Thurber   +5 more
openalex   +1 more source

JSKN003, A NOVEL BIPARATOPIC ANTI-HER2 ANTIBODY-DRUG CONJUGATE, EXHIBITS POTENT ANTITUMOR EFFICACY [PDF]

, 2023
Pilin Wang, Kangping Guo, Jianjian Peng, Jie Sun, Ting Xu   +4 more
openalex   +1 more source